Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer.

Fanconi Anemia: A Signal Transduction and DNA Repair Pathway

Fanconi anemia (FA) is a fascinating, rare genetic disorder marked by congenital defects, bone marrow failure, and cancer susceptibility. Research in recent years has led to the elucidation of FA as a DNA repair disorder and involved multiple pathways as well as having wide applicability to common cancers, including breast, ovarian, and head and neck. This review will describe the clinical aspe...

Fanconi anemia (FA)-associated proteins FANCF and FANCD2 are important components of the FA pathway of DNA crosslink repair. FANCF and FANCD2 have been found to be involved in drug-resistant multiple myeloma, ovarian cancer, non-small-cell lung cancer, and head and neck

The Fanconi anemia (FA)-associated proteins FANCF and FANCD2 are important components of the FA pathway of DNA crosslink repair. FANCF and FANCD2 have been found to be involved in drug-resistant multiple myeloma, ovarian cancer, non-small-cell lung cancer, and head and neck cancer. However, it is unclear whether these two genes participate in adriamycin (ADR)-resistant leukemia. Therefore, the ...

Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.

Patients with the rare genetic disease, Fanconi anemia (FA), are highly susceptible to squamous cell carcinomas arising at multiple anatomic sites including the head and neck region. Human papillomaviruses (HPVs), particularly HPV16, are associated with ∼20% of head and neck squamous cell carcinomas (HNSCCs) in the general population. Some but not other investigators have reported that HNSCCs i...

Enhanced Frequency of Sister Chromatid Exchanges Induced by Diepoxybutane Is Specific Characteristic of Fanconi Anemia Cellular Phenotype

A genome - wide siRNA screen identi ies the FA / BRCA pathway as the strongest predictor of cisplatin response in head and neck cancer cells

A genome-wide siRNA screen identiiies the FA/BRCA pathway as the strongest predictor of cisplatin response in head and neck cancer cells. ABSTRACT Objective: Patients with advanced head and neck squamous cell carcinoma (HNSCC) are generally treated with cisplatin-containing chemoradiation protocols. Although cisplatin is a low-priced and often used addition to radiation, it causes severe toxici...